BioMarin Pharmaceutical
Stock Forecast, Prediction & Price Target

BioMarin Pharmaceutical (BMRN) stock Price Target by analysts

Last Year
Average Price Target

$91.85

Potential upside: 61.13%

Based on 10 analysts

BioMarin Pharmaceutical price prediction

Strike.market

What is BioMarin Pharmaceutical stock analysts` prediction?

BioMarin Pharmaceutical stock forecast: Based on 10 Wall Street analysts` predicted price targets for BioMarin Pharmaceutical in the last 3 months, the avarage price target is $91.85, with a high forecast of $NaN. The average price target represents a 61.13% change from the last price of $57.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

BioMarin Pharmaceutical stock Price Target by analysts

Full breakdown of analysts given BioMarin Pharmaceutical price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Olivia Brayer
Cantor Fitzgerald
50%
1/2
10 months ago $90 57.89% upside $67 TheFly
Previous targets (1)
David Lebowitz
Citigroup
0%
0/2
10 months ago $81 42.10% upside $69.91 StreetInsider
Previous targets (1)
Jack Allen
Robert W. Baird
0%
0/2
10 months ago $65 14.03% upside $69.91 StreetInsider
Previous targets (1)
Danielle Brill
Raymond James
0%
0/1
11 months ago $79 38.59% upside $69.6 TheFly
Previous targets (0)
Gena Wang
Barclays
0%
0/2
11 months ago $86 50.87% upside $69.51 StreetInsider
Previous targets (1)
David Lebowitz
Citigroup
0%
0/2
12 months ago $93 63.15% upside $71.14 StreetInsider
Previous targets (1)
William Pickering
Bernstein
0%
0/1
12 months ago $90 57.89% upside $69.86 TheFly
Previous targets (0)
Joon Lee
Truist Financial
0%
0/1
12 months ago $90 57.89% upside $71.21 StreetInsider
Previous targets (0)
Kostas Biliouris
BMO Capital
0%
0/2
12 months ago $115 101.75% upside $71.13 StreetInsider
Previous targets (1)
George Farmer
Scotiabank
0%
0/3
12 months ago $78 36.84% upside $71.21 StreetInsider
Previous targets (2)
Gena Wang
Barclays
0%
0/2
12 months ago $110 92.98% upside $69.86 StreetInsider
Previous targets (1)
Christopher Raymond
Raymond James
0%
0/3
about 1 year ago $122 114.03% upside $86.74 StreetInsider
Previous targets (2)
George Farmer
Scotiabank
0%
0/3
about 1 year ago $95 66.66% upside $86.75 StreetInsider
Previous targets (2)
Christopher Raymond
Raymond James
0%
0/3
about 1 year ago $107 87.71% upside $88.69 StreetInsider
Previous targets (2)
Paul Matteis
Stifel Nicolaus
0%
0/2
about 1 year ago $115 101.75% upside $93.84 TheFly
Previous targets (1)
William Pickering
Tudor Pickering
0%
0/2
about 1 year ago $110 92.98% upside $94.2 StreetInsider
Previous targets (1)
Paul Matteis
Stifel Nicolaus
0%
0/2
about 1 year ago $112 96.49% upside $85.99 Benzinga
Previous targets (1)
Cory Kasimov
Evercore ISI
0%
0/2
about 1 year ago $115 101.75% upside $85.99 Benzinga
Previous targets (1)
Whitney Ijem
Canaccord Genuity
0%
0/1
about 1 year ago $93 63.15% upside $80.47 TheFly
Previous targets (0)
Mohit Bansal
Wells Fargo
0%
0/1
about 1 year ago $115 101.75% upside $85.25 TheFly
Previous targets (0)
William Pickering
Tudor Pickering
0%
0/2
over 1 year ago $91 59.64% upside $78.87 TheFly
Previous targets (1)
Jack Allen
Robert W. Baird
0%
0/2
over 1 year ago $72 26.31% upside $76.97 StreetInsider
Previous targets (1)
Cory Kasimov
Evercore ISI
0%
0/2
over 1 year ago $113 98.24% upside $80.5 TheFly
Previous targets (1)
George Farmer
Scotiabank
0%
0/3
over 1 year ago $85 49.12% upside $91.2 StreetInsider
Previous targets (2)
Eliana Merle
UBS
0%
0/1
over 1 year ago $119 108.77% upside $89.49 StreetInsider
Previous targets (0)
Kostas Biliouris
BMO Capital
0%
0/2
about 2 years ago $102 78.94% upside $85.89 StreetInsider
Previous targets (1)
Christopher Raymond
Raymond James
0%
0/3
almost 3 years ago $128 124.56% upside $92.1 TheFly
Previous targets (2)
Robyn Karnauskas
Truist Financial
0%
0/1
almost 3 years ago $133 133.33% upside $89.41 TheFly
Previous targets (0)
Olivia Brayer
Cantor Fitzgerald
50%
1/2
about 3 years ago $110 92.98% upside $87.85 TheFly
Previous targets (1)
Matthew Harrison
Morgan Stanley
66.67%
2/3
over 3 years ago $113 98.24% upside $80.5 StreetInsider
Previous targets (2)
Matthew Harrison
Morgan Stanley
66.67%
2/3
over 3 years ago $10 -82.45% downside $81.49 TipRanks Contributor
Previous targets (2)
Joshua Schimmer
Evercore ISI
100%
1/1
over 3 years ago $105 84.21% upside $85.37 TipRanks Contributor
Previous targets (0)
Matthew Harrison
Morgan Stanley
66.67%
2/3
over 3 years ago $90 57.89% upside $84.86 StreetInsider
Previous targets (2)
Geoff Meacham
Bank of America Securities
0%
0/1
over 3 years ago $120 110.52% upside $84.39 StreetInsider
Previous targets (0)
Phil Nadeau
Cowen & Co.
0%
0/1
over 3 years ago $135 136.84% upside $88.38 StreetInsider
Previous targets (0)
Tiago Fauth
Credit Suisse
100%
1/1
almost 4 years ago $105 84.21% upside $90.3 TheFly
Previous targets (0)
Debjit Chattopadhyay
Guggenheim
0%
0/1
almost 4 years ago $120 110.52% upside $91.47 TheFly
Previous targets (0)

BioMarin Pharmaceutical Financial Estimates

BioMarin Pharmaceutical Revenue Estimates

BioMarin Pharmaceutical EBITDA Estimates

BioMarin Pharmaceutical Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$1.84B
 
N/A
$2.09B
 
13.52%
$2.41B
 
15.41%
Avg: $3.07B
Low: $2.84B
High: $3.24B
avg. 27.28%
Avg: $3.42B
Low: $3.23B
High: $3.58B
avg. 11.30%
Avg: $3.78B
Low: $3.56B
High: $3.95B
avg. 10.30%
Avg: $4.17B
Low: $3.93B
High: $4.36B
avg. 10.31%
Net Income
 
% change YoY
$-64.08M
 
N/A
$141.56M
 
320.91%
$167.64M
 
18.42%
Avg: $501.80M
Low: $101.54M
High: $773.46M
avg. 199.32%
Avg: $683.44M
Low: $210.75M
High: $1.05B
avg. 36.19%
Avg: $879.22M
Low: $813.59M
High: $932.13M
avg. 28.64%
Avg: $1.15B
Low: $1.06B
High: $1.22B
avg. 30.91%
EBITDA
 
% change YoY
$48.02M
 
N/A
$159.51M
 
232.14%
$310.28M
 
94.51%
Avg: $119.60M
Low: $110.58M
High: $125.88M
avg. -61.45%
Avg: $133.13M
Low: $125.48M
High: $139.29M
avg. 11.30%
Avg: $146.84M
Low: $138.41M
High: $153.64M
avg. 10.30%
Avg: $162.00M
Low: $152.70M
High: $169.50M
avg. 10.31%
EPS
 
% change YoY
-$0.35
 
N/A
$0.76
 
317.14%
$0.89
 
17.10%
Avg: $2.59
Low: $0.53
High: $4.04
avg. 191.07%
Avg: $3.39
Low: $1.1
High: $5.5
avg. 30.99%
Avg: $4.59
Low: $4.25
High: $4.87
avg. 35.22%
Avg: $6.01
Low: $5.56
High: $6.37
avg. 30.91%
Operating Expenses
 
% change YoY
$1.45B
 
N/A
$1.57B
 
7.72%
$1.74B
 
11.17%
Avg: $1.23B
Low: $1.14B
High: $1.29B
avg. -29.37%
Avg: $1.37B
Low: $1.29B
High: $1.43B
avg. 11.30%
Avg: $1.51B
Low: $1.42B
High: $1.58B
avg. 10.30%
Avg: $1.67B
Low: $1.57B
High: $1.74B
avg. 10.31%

FAQ

What is BioMarin Pharmaceutical stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 73.77% in 2025-2028.

We have gathered data from 17 analysts. Their low estimate is 101.54M, average is 501.80M and high is 773.46M.

What is BioMarin Pharmaceutical stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 14.80% in 2025-2028.

We have gathered data from 19 analysts. Their low revenue estimate is $2.84B, average is $3.07B and high is $3.24B.

What is BioMarin Pharmaceutical stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 72.05% in 2025-2028.

We have gathered data from 17 analysts. Their low earnings per share estimate is $0.53, average is $2.59 and high is $4.03.

What is the best performing analyst?

In the last twelve months 10 analysts have been covering BioMarin Pharmaceutical stock. The most successful analyst is Olivia Brayer whose win rate is 50%. He has correctly predicted 1/2 price targets.